 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
Australia's reporting season delivered uneven results, sharp share price reactions and a more cautious outlook from many li...
Times Media Australia has expanded its network of independent local and destination publications with the establishment of ...
Fly-in fly-out work is usually described in numbers. Two weeks on, one week off. Eight days on, six days off. Fourteen d...
The Times recently argued that Australia should keep building the data centres the AI economy requ...
The Australian-born fitness brand is bringing its global competition home, with athletes from across...
Medical experts issue an urgent wake-up call for Women’s Health Week, revealing how everyday delay t...
Every Australian family with school-aged children knows the pattern. Look at an airfare, hotel ro...
Medical experts issue an urgent wake-up call for Women’s Health Week, revealing how everyday delay t...
After more than two decades spent perfecting burgers, Grill'd is entering new territory. The Aust...
Two Years Later looks, initially, like a romantic television series. It is considerably more inte...